Pfizer Inc. $PFE Shares Bought by JGP Wealth Management LLC

JGP Wealth Management LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 5.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,430 shares of the biopharmaceutical company’s stock after acquiring an additional 1,193 shares during the quarter. JGP Wealth Management LLC’s holdings in Pfizer were worth $568,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter worth about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the first quarter worth about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the first quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.35.

Pfizer Trading Down 0.8%

Shares of PFE stock opened at $24.53 on Wednesday. The stock has a market cap of $139.44 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.82. The firm’s 50 day moving average price is $24.88 and its two-hundred day moving average price is $24.12.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.